PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer

CONCLUSION: The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.PMID:38513188 | DOI:10.1200/JCO.23.01940

Source: Clinical Genitourinary Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Erica L Mayer Yue Ren Nikhil Wagle Reshma Mahtani Cynthia Ma Angela DeMichele Massimo Cristofanilli Jane Meisel Kathy D Miller Yara Abdou Elizabeth C Riley Rubina Qamar Priyanka Sharma Sonya Reid Natalie Sinclair Meredith Faggen Caroline C Block Naomi Ko Source Type: research